Experience with pioglitasone (actos) in the treatment of polycystic ovary syndrome

: The paper presents the authors 'data obtained from examinations of 1 7 patients aged 15 to 36 years who had polycystic ovary syndrome (PCOS) and insulin resistance before and after therapy with pioglitasone in a daily dose of 30 mg, regardless of the time of a meal, for 3 months. The study was undertaken to examine the effects of pioglitasone on carbohydrate and lipid metabolic parameters, as well as on the hormonal parameters of ovarian function and on the basic clinical manifestations in patients with PCOS. Elimination of insulin resistance with the sensitizers of the action of insulin, such as pioglitasone, contributes to the normalization of reproductive function in most patients with PCOS and insulin resistance.